oprx-106
Recombinant proteinexperimental
Clinical trial activity
2 trials · 1 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
1
Phase 3
0
Phase 4
0
Earliest trial started Jul 1, 2014 (NCT02107833)
Timeline
Indications
Mechanism of action
- TNF-alphaINHIBITOR
TNF inhibitor
Chemistry & pharmacology
- Multi-specific
- No
Oral
No
Parenteral
No
Topical
No
Also known as
- oprx-106
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT02768974 | Phase 2 | Sep 1, 2016 | Protalix |
| NCT02107833 | Phase 1 | Jul 1, 2014 | Protalix |
Showing 2 of 2 trials
Page 1 / 1
Organizations
Research & Development (1)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Protalix | For profit | 2 | 2 | 2 | 2014 |
1 organizations
Page 1 / 1